MedTrace Logo

This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)

NCT06817915 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-02-10

No results posted yet for this study

Summary

This is a research plan from the University of Munich (LMU) that aims to study how the use of AI reports can impact ophthalmologists' decisions regarding treatment for patients with neovascular age-related macular degeneration (nAMD). This disease is a leading cause of vision loss, and while anti-VEGF treatments are effective, they require careful monitoring and retreatment decisions to maximize benefits.

The study will involve up to 1000 ophthalmologists with varying levels of expertise. These ophthalmologists will review SD-OCT scans and make treatment decisions before and after reviewing AI-generated reports. The primary objective is to compare these decisions and see how the AI reports influence them. Secondary objectives include assessing the accuracy and safety of the AI reports.

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

BEHAVIORAL

AI assisted assessment of SD-OCT scans

AI 2nd opinion report on nAMD treatment planning

Sponsors & Collaborators

  • Deepeye Medical GmbH

    collaborator INDUSTRY

  • Technomics Research

    collaborator INDUSTRY

  • M3 Macula Monitor Muenster

    collaborator UNKNOWN

  • Johannes Schiefelbein

    lead OTHER

Principal Investigators

  • Director the Eye Clinic · LMU Klinikum Eye Clinic

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06817915 on ClinicalTrials.gov